Grant: Operating Grant
University of Calgary
$669,215.00
A Unifying Mechanism for the Anti-inflammatory Effect of Phosphodiesterase 4 Inhibitors in Chronic Obstructive Pulmonary Disease
FY 2008-09
Summary
Phosphodiesterase (PDE) 4 inhibitors are a new class of drugs being developed for the treatment of chronic obstructive pulmonary disease (COPD), which is more commonly referred to as bronchitis and/or emphysema. The results of several clinical trials in subjects with COPD suggest that PDE4 inhibitors can slow the development of this disease. Hoewever, exactly how this novel class of drugs do this has not been investigated and, accordingly, is not understood. Clearly, a complete appreciation of how PDE4 inhibitors work in COPD is a desirable objective if their effectiveness is to be optimized or, ideally, enhanced.
Department
Program
Operating Grant
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
170849
Name
Giembycz Mark A
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Respiratory System
Projecttitle
A Unifying Mechanism for the Anti-inflammatory Effect of Phosphodiesterase 4 Inhibitors in Chronic Obstructive Pulmonary Disease
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$669,215
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
15-Lipoxygenase; Airways Inflammation; Copd; Cyclic Nucleotides; Peroxisome Proliferator-Activated Recepotor Gamma; Phosphodiesterase 4 Inhibitors
Abstract
Phosphodiesterase (PDE) 4 inhibitors are a new class of drugs being developed for the treatment of chronic obstructive pulmonary disease (COPD), which is more commonly referred to as bronchitis and/or emphysema. The results of several clinical trials in subjects with COPD suggest that PDE4 inhibitors can slow the development of this disease. Hoewever, exactly how this novel class of drugs do this has not been investigated and, accordingly, is not understood. Clearly, a complete appreciation of how PDE4 inhibitors work in COPD is a desirable objective if their effectiveness is to be optimized or, ideally, enhanced.
Competitiondate
200809
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Giembycz, Mark A
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $669,215~ $0~
